These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23116602)

  • 21. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
    Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
    Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib mesylate for the treatment of chronic myeloid leukemia.
    Soverini S; Martinelli G; Iacobucci I; Baccarani M
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):853-64. PubMed ID: 18533795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased expression of protease-activated receptor 1 (PAR-1) in human leukemias.
    Veiga Cde S; Carneiro-Lobo TC; Coelho CJ; Carvalho SM; Maia RC; Vasconcelos FC; Abdelhay E; Mencalha AL; Ferreira AF; Castro FA; Monteiro RQ
    Blood Cells Mol Dis; 2011 Mar; 46(3):230-4. PubMed ID: 21216163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of FHIT expression in chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios MB; Croce CM; Albitar M
    Clin Cancer Res; 1999 Dec; 5(12):4059-64. PubMed ID: 10632340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
    Moravcová J; Zmeková V; Klamová H; Voglová J; Faber E; Michalová K; Rabasová J; Jarosová M
    Leuk Res; 2004 Apr; 28(4):415-9. PubMed ID: 15109543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
    Tauchi T; Kizaki M; Okamoto S; Tanaka H; Tanimoto M; Inokuchi K; Murayama T; Saburi Y; Hino M; Tsudo M; Shimomura T; Isobe Y; Oshimi K; Dan K; Ohyashiki K; Ikeda Y;
    Leuk Res; 2011 May; 35(5):585-90. PubMed ID: 21145591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
    Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
    Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
    Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
    Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients].
    Creutzig U; Ritter J; Zimmermann M; Klingebiel T
    Klin Padiatr; 1996; 208(4):236-41. PubMed ID: 8926689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
    Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced-phase chronic myeloid leukemia.
    Cortes J; Kantarjian H
    Semin Hematol; 2003 Jan; 40(1):79-86. PubMed ID: 12563614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients].
    Zhou L; Wang AH; Wang L; You JH; Li JM; Shen ZX
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):13-7. PubMed ID: 18512309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of long-term treatment outcome and related factors in 95 chronic myeloid leukemia patients treated with imatinib].
    Wang GR; Zhao YZ; Qian LS; Zou DH; Li R; Mi YC; Wang XX; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):18-22. PubMed ID: 18512310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malondialdehyde and protein carbonyl as biomarkers for oxidative stress and disease progression in patients with chronic myeloid leukemia.
    Ahmad R; Tripathi AK; Tripathi P; Singh S; Singh R; Singh RK
    In Vivo; 2008; 22(4):525-8. PubMed ID: 18712183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.
    Wu B; Zhou S; Song L; Liu X
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):364-6. PubMed ID: 12408765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of symptom burden on patient quality of life in chronic myeloid leukemia.
    Cella D; Nowinski CJ; Frankfurt O
    Oncology; 2014; 87(3):133-47. PubMed ID: 25012261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.